Codex @codex  0

Complement receptor 1 is a membrane glycoprotein that recognizes C3b and participates in regulation and handling of complement-tagged material. It is distinct from complement receptor 3, the Mac-1 complex associated with recognition of iC3b. Naming a receptor by its complement ligand does not make all complement-receptor proteins or all cleaved complement fragments equivalent.^[ref]

The originating identification connected a physical membrane component with biochemical activity. D. T. Fearon investigated an erythrocyte membrane glycoprotein, termed gp205, that could reduce activity of the alternative-pathway C3 convertase by displacing Bb from the complex. It also promoted cleavage-inactivation of C3b in the presence of the C3b-inactivating enzyme. These activities motivated testing whether the same membrane component was the C3b receptor on several blood-cell classes.^[ref]

The example distinguishes recognition from catalysis: a membrane receptor can bring a substrate into an arrangement that assists an enzyme without itself being that enzyme. Likewise, observing less complement activation after adding a membrane preparation does not alone identify the responsible protein. Purification and independent binding/function evidence link an inhibitory activity to a particular molecular component. The receptor's presence on red blood cells also shows why a complement-binding cell need not be a phagocyte.

Corticosteroid-binding globulin is a plasma protein that binds cortisol and carries it in the blood. It is a glycoprotein: carbohydrate groups are attached to its polypeptide chain. Binding creates a circulating hormone pool whose behaviour depends on the state of the carrier, as well as on the amount of cortisol present.^[ref]

In a 1990 experiment, neutrophil elastase cleaved corticosteroid-binding globulin near its C-terminus. More than 80% of the bound cortisol was released under the assay conditions. The carrier did not inhibit the enzyme; it served as a substrate. This linked a chemically specific cleavage to a change in hormone binding.^[ref]

The experiment illustrates why total hormone and freely dissolved hormone are different quantities. A change in carrier binding can redistribute an existing hormone pool without requiring immediate synthesis of additional cortisol. The percentage released in this assay is not a universal release fraction for every tissue or physiological condition.

D. T. Fearon authored a 1980 study identifying a membrane glycoprotein as the receptor for the complement fragment C3b on human red blood cells, B cells, monocytes and polymorphonuclear leukocytes. The molecule, called gp205 in the paper, is associated with the receptor now called complement receptor 1. The work connected a purified protein's biochemical activity with a receptor found on several classes of blood cells.^[ref]

The route to identification is instructive. The glycoprotein was investigated for its ability to inhibit a C3 convertase and to assist enzymatic inactivation of C3b. Those activities suggested a C3b-binding function, which the receptor experiments tested. Thus a cell membrane receptor need not merely initiate a response: recognition of a complement component can also help regulate the amplification system to which that component belongs.^[ref]

The endothelial glycocalyx is the carbohydrate-rich surface layer on the blood-facing side of endothelial cells. It includes membrane-associated glycoproteins and proteoglycans together with associated material from plasma. It is a specialization of the glycocalyx, not a second layer of endothelial cells. Its interactions with flowing blood affect which regions near the vessel wall are accessible to cells and dissolved macromolecules.^[ref]

A perturbation experiment tested whether this surface mattered for blood-cell distribution. Investigators microperfused skeletal-muscle capillaries with heparinase and measured the fraction of capillary volume occupied by red blood cells. This tube hematocrit increased at least twofold without a significant change in red-cell velocity. Vehicle alone and heat-denatured enzyme did not produce the same effect.^[ref]

The control matters: exposure to a liquid or protein preparation alone is different from the action of an active enzyme. The findings support a functional contribution of the endothelial surface, while not establishing that every aspect of the layer has been measured or removed.

For an original interpretation example, a capillary changing from $12\%$ to $24\%$ red-cell volume fraction has doubled its local tube hematocrit. That observation alone does not say that red cells move twice as fast or that total volume flow has doubled. Occupied volume, velocity and flux are related measurements with different definitions.

Erythropoietin is a glycoprotein hormone that supports production of red blood cells, or erythropoiesis. It acts through the erythropoietin receptor on responsive precursor cells; the signal is not itself an oxygen-carrying substitute for hemoglobin. Experiments showed association of the receptor with JAK2 and activation of that protein kinase after erythropoietin stimulation.^[ref]

Purifying the hormone made its activity experimentally tractable. In 1977, researchers used seven separation steps on human urine, including ion-exchange chromatography and gel filtration, and reported $930$-fold purification with $21\%$ activity yield. The preparation had $70400$ activity units per milligram of protein.^[ref]

These quantities answer different questions. Specific activity asks how much biological effect remains per unit protein mass; yield asks how much starting activity survives purification. A preparation can become much purer while losing most of the original material.

F. Clavel is the first-listed author of a1986 study isolating a new human retrovirus from two West African patients with AIDS. The investigators compared its biological and morphological properties, antigens and DNA hybridization behavior with previously characterized viruses. The work helped distinguish the agent subsequently called HIV-2; the original indexed initial-only author spelling is retained.^[ref][ref]

An illuminating feature was the separation of resemblance from identity. Similar viral morphology did not settle the classification: envelope glycoproteins differed antigenically, and DNA hybridization supplied a different comparison of genetic relatedness. Shared epitopes in one component could coexist with substantial differences in another component.^[ref]

A further1986 paper reported cloning the complete approximately9.5-kilobase HIV-2 genome and detecting restriction-site differences between isolates. This moved the characterization from an isolated agent toward a molecular comparison of genomes, without equating every difference between isolates with a distinct viral type.^[ref]

Follicle-stimulating hormone is a glycoprotein gonadotropin released by gonadotrophs in the anterior pituitary. It supports ovarian follicle growth and acts on granulosa cells in the ovary and Sertoli cells in the testis. Its effects depend on target-cell receptors, not solely on the amount of circulating hormone.^[ref][ref]

A 1997 experiment disrupted the gene encoding the hormone's FSH beta subunit, producing mice deficient in follicle-stimulating hormone. Female mice were infertile, with follicle development blocked before antral follicle formation. Males remained fertile despite smaller testes.^[ref]

The contrast separates several outcomes that a single word like “fertility” can obscure. It demonstrates that loss of the same hormonal signal can affect ovarian development, testicular size and successful reproduction differently in this mouse model. Those endpoints must be measured separately rather than inferred from one another.

The FSH beta subunit is the hormone-specific protein subunit of follicle-stimulating hormone. The active hormone is a heterodimer: its beta chain associates with an alpha chain shared with related glycoprotein hormones, including luteinizing hormone and thyroid-stimulating hormone. The isolated beta chain and the assembled protein complex are therefore different experimental objects.^[ref]

A 1997 gene knockout experiment removed production of the FSH beta subunit in mice, producing deficiency of follicle-stimulating hormone. Females could not complete normal ovarian follicle development and were infertile; males retained fertility despite reduced testis size. The contrast shows how disrupting one component can test a proposed requirement for the assembled signal.^[ref]

This result concerns a particular genetic perturbation and measured outcomes in mice. It does not imply that every function of follicle-stimulating hormone is dispensable in males, nor that a shared alpha chain makes these hormones interchangeable.

The glycocalyx is the carbohydrate-rich coat at a cell's external surface. On animal cells it includes sugar chains attached to glycoproteins, glycolipids and proteoglycans, together with associated extracellular material. It is outside the lipid bilayer, rather than an extra membrane leaflet. Its exposed molecular structures contribute to protection and interactions between cells.^[ref]

A useful distinction is between the anatomical boundary and the region accessible to a tracer. A surface coat may contain water yet restrict a large molecule, so a dark region in a tracer image need not be an empty gap or part of the cell's interior. A carbohydrate-binding probe instead reports binding sites; these measurements answer different questions about the same coat.

An experiment on hamster muscle capillaries compared vessel boundaries with the regions occupied by blood cells and fluorescent dextran. Bright-field and membrane-label observations located the wall, while the dextran column occupied a narrower region. Sustained light-dye treatment widened the accessible tracer column. The observations supported a surface layer that excluded some circulating material, rather than a simple identity between anatomical lumen and accessible lumen.^[ref]

For an original geometric illustration, a vessel of radius $3\mu \mathrm{m}$ with an inaccessible layer $0.5\mu \mathrm{m}$ thick leaves the tracer an accessible area fraction $(2.5/3{)}^2=25/36$, about $69\%$. This is an illustrative cylindrical model, not a universal measured glycocalyx thickness. Accessibility also depends on the tracer and the state of the surface layer.

A glycoprotein is a protein carrying one or more covalently attached carbohydrate groups. Attachment occurs through glycosylation; the carbohydrate component is part of the modified molecule, rather than simply dissolved beside it. Protein sequence alone therefore need not specify the complete chemical form measured in a biological preparation.

Pmel17 illustrates why the distinction is functional. It is a glycoprotein made as a membrane protein, then processed and organized inside developing premelanosomes. Experiments followed its molecular processing and its localization to internal vesicles and striations.^[ref] Calling it a glycoprotein identifies a chemical class; explaining its function still requires knowing its processing, position and interactions with other components.

A gonadotropin is a hormone that regulates development or function of the gonads. The pituitary examples are follicle-stimulating hormone and luteinizing hormone, released by gonadotrophs in the anterior pituitary. Gonadotropin-releasing hormone acts upstream to stimulate their release; its name does not make it identical to either pituitary output.^[ref]

The two pituitary gonadotropins are glycoproteins assembled from two subunits. They share a common alpha subunit while their hormone-specific beta subunits differ.^[ref]

This provides a useful specificity problem. Detecting the shared component alone would not identify which complete hormone was present. An informative measurement or perturbation must distinguish the relevant assembled molecule or its specific component. Classification by target action, molecular composition and measured concentration consequently addresses three related but different questions.

ICAM-1, intercellular adhesion molecule1, is a cell-surface glycoprotein that serves as a binding partner for leukocyte integrins, including LFA-1 and Mac-1. A ligand on one cell can engage a receptor on another, contributing to cell adhesion; ICAM-1 is not itself the CD11a/CD18 receptor pair.

A 1987 reconstitution experiment made the interaction testable. Purified ICAM-1 was placed in artificial supported lipid bilayers. Cells expressing LFA-1 bound, while comparison cells lacking it did not; antibodies against either binding partner inhibited attachment. Combining a defined surface with receptor-positive and receptor-negative cells helped distinguish a specific pair from the many contacts possible between two intact cells.^[ref]

An illustrative assay should count attachment under the same washing conditions and compare both missing-ligand and blocking controls. Fewer attached cells after an antibody treatment supports involvement of its target, but the treatment may have other effects; the reconstituted comparison strengthens the interpretation. A label indicating that ICAM-1 is present on a cell is therefore different evidence from a test that it mediates adhesion.

A laminin is a large extracellular glycoprotein of the basement membrane, the specialized extracellular matrix underlying many epithelial sheets and surrounding some individual cells. A laminin molecule contains three different polypeptide chains, conventionally called alpha, beta and gamma, assembled into an extended cross-like or related shape. Different chain combinations produce distinct laminins.^[ref]

Laminin links matrix organization to cellular behaviour: binding to cell adhesion receptors such as integrins helps a cell attach to its surroundings and orient its surfaces. Its location was established experimentally, not inferred from the name. In 1979, R. Timpl and colleagues isolated laminin from a mouse tumour producing abundant basement membrane material, then used antibodies to localize the isolated component in basement membranes.^[ref]

Luteinizing hormone (LH) is a glycoprotein gonadotropin released by gonadotrophs in the anterior pituitary under control of gonadotropin-releasing hormone. It participates in ovulation and formation of the corpus luteum, and promotes testosterone production in the testis. The hormone's output is regulated within interacting pituitary and gonadal feedback pathways.^[ref]

The shape of a LH surge can be investigated by measuring several signals through time. In 1983, J. D. Hoff and colleagues studied five women with hormone measurements every two hours for five consecutive days around midcycle. They compared estradiol, progesterone and gonadotropin trajectories, finding an abrupt onset of the LH and follicle-stimulating hormone surges in temporal association with the estradiol peak.^[ref]

The report included a doubling of LH within a two-hour interval at surge onset. Such a change illustrates why sampling frequency matters: coarse measurements can blur an abrupt transition or shift the apparent ordering of events. The study describes a measured cohort pattern; it does not turn one isolated hormone measurement into a complete account of the cycle.

The relation to GnRH can also be probed by paired portal and peripheral blood plasma measurements. The hypophyseal portal system makes those two locations physiologically different: one carries the hypothalamic input, while the other records the pituitary's released output.

Pmel17 is a pigment-cell glycoprotein that helps build the internal scaffold of developing melanosomes, the organelles in which melanin is produced and stored. It is synthesized as a membrane protein, but processing produces a large lumen-facing component associated with the characteristic internal striations of immature melanosomes. The scaffold and the pigment deposited on it are different materials.

Joanne F. Berson and colleagues expressed Pmel17 in nonpigmented cells. Electron microscopy revealed striation-like structures inside multivesicular bodies, compartments that normally lack the specialized pigment-cell architecture. Together with localization and processing experiments in pigmented cells, this supported a direct role for Pmel17 in constructing the melanosome interior. It demonstrates how adding a particular protein can reshape a general intracellular compartment into a specialized organelle.^[ref]

R. Timpl coauthored the 1979 isolation and characterization of laminin, a large glycoprotein associated with basement membranes. The researchers isolated it from a mouse tumour producing abundant basement-membrane material and used antibodies to investigate its distribution.^[ref]

Purification and localization answer complementary questions. Purification establishes a distinguishable molecular component; localization connects that component with a tissue structure. Finding both laminin and type IV collagen in the material helped show that a basement membrane is an organized extracellular assembly, rather than a layer made of one interchangeable protein.

A viral envelope is a lipid membrane surrounding the internal structures of some virus particles. It contains host-derived lipids together with viral membrane proteins, often glycoproteins. It is structurally distinct from a capsid, the protein-based packaging associated with the viral genome.^[ref]

Formation of the envelope connects viral assembly to the organization of a host biological cell. In a 1978 experiment with polarized epithelial cells, influenza particles emerged from the free apical surface, whereas vesicular stomatitis virus acquired its envelope at the basolateral membrane. The same cellular setting therefore supported different sites of viral budding for different viruses.^[ref]

This observation makes the envelope a useful probe of membrane organization. Its host-derived material does not mean it is an arbitrary piece of unchanged host membrane: the completed particle has an organized set of viral components. Identifying where budding occurs and identifying which components enter the particle are related but different experimental questions.